Oligonucleotides are short chain RNA or DNA typically made by using automated synthesizers. Oligonucleotides therapy is different from conventional medicine since it can inhibit the expression of specific genes and their development takes place with the raw chemical modified artificial nucleus acids. This lead to development of brand new oligonucleotides targeting certain genes and treating chronic diseases. They are broadly used in applications such as infectious diseases, oncology, kidney diseases, and cardiovascular diseases.
The "Global Oligonucleotide-Based Therapies Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the oligonucleotide-based therapies market with detailed market segmentation by type, application, and geography. The report provides key statistics on the market status of the leading oligonucleotide-based therapies market players and offers key trends and opportunities in the market.
Based on type, the global oligonucleotide-based therapies market is segmented into antisense, ribozymes, aptamers, miRNA, CpG/Immunostimulatory and RNAi.
On the basis of application, the market is bifurcated into infectious diseases, oncology, neurodegenerative disorders, cardiovascular diseases, kidney diseases and others.
MARKET DYNAMICS Drivers
Increasing incidence of cancer and infectious disease and the necessity for personalized medicines for neurodegenerative disorders is expected to drive the oligonucleotide-based therapies market.
Increasing demand for novel therapies and growing innovative new oligonucleotides boosts the market growth.
Rising licensing and collaboration activities and growing demand for advanced technologies in oligonucleotide therapeutics fuel the market growth.
The incapability to detect minor antibodies.
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The oligonucleotide-based therapies market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the oligonucleotide-based therapies market in these regions.
IMPACT OF COVID-19 ON OLIGONUCLEOTIDE-BASED THERAPIES MARKET
COVID-19 first began in Wuhan (China) during December 2019, and since then, it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, UK, Turkey, Italy, and Spain are some of the worst affected countries in terms of confirmed cases and reported deaths. With the outbreak of pandemic, a slight decrease in the oligonucleotide-based drugs sales was seen due to worldwide restrictions and lockdown imposed during the COVID-19 pandemic. However, the pharmaceutical and biopharmaceutical companies, along with the players of the oligonucleotide market, came forward to contribute to research efforts worldwide by providing oligo products. These products were used for development of test kits, treatments, and vaccines that target the novel coronavirus infection. The various initiatives by the market players and usage of a wide range of oligonucleotide products like probes and primers in coronavirus research has helped researchers gain a better insight of the virus. Hence, the oligonucleotide market is estimated to witness growth in coming years.
Get more information on this report :
The report covers key developments in the oligonucleotide-based therapies market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market players from oligonucleotide-based therapies market are anticipated to have lucrative growth opportunities in the future with the rising demand for oligonucleotide-based therapies in the global market.
The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the oligonucleotide-based therapies market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.
miRagen Therapeutics, Inc.
Ionis Pharmaceuticals, Inc.
Gilead Sciences, Inc.
Regulus Therapeutics Inc.
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
Get more information on this report :
The List of Companies
1. PCI Biotech
3. InteRNA Technologies
5. miRagen Therapeutics, Inc.
6. Ionis Pharmaceuticals, Inc.
7. Aligos Therapeutics
8. Gilead Sciences, Inc.
9. Biogen Inc.
10. Regulus Therapeutics Inc.